Journal of Chinese Integrative Medicine ›› 2009, Vol. 7 ›› Issue (4): 306-308.doi: 10.3736/jcim20090402
• Original Clinical Research • Previous Articles Next Articles
| [1] | Zhang XY, Xu LY, Wang H, Zhu YZ, Liu Z, Yue WT, Tang JF, Wu W, Liu Z, Wu YH, Zhang CY, Shi YK, Wang MZ, Shi HL, Li MZ, Meng QY, Guo LL, Wang JH, Li XB . The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced non-small-cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2008,11(2):206-213 |
| 张新勇, 徐丽艳, 汪惠, 朱允中, 刘喆, 岳文涛, 唐俊舫, 武玮, 刘赞, 吴羽华, 张春彦, 石远凯, 王孟昭, 史鹤玲, 李明智, 孟弃逸, 郭丽丽, 王敬慧, 李雪冰 . EGFR基因突变与酪氨酸激酶抑制剂疗效及预后之间的关系[J]. 中国肺癌杂志, 2008,11(2):206-213 | |
| [2] | Liu YF, Guan XX, Chen LB, Chen YT . Study on ERCC1, XPD and XPA polymorphisms for prediction of platinum-based chemotherapy sensitivity in non-small cell lung cancer[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2008,15(17):1285-1288 |
| 柳艳飞, 管晓翔, 陈龙邦, 陈一天 . ERCC1与XPD和XPA的遗传多态性对非小细胞肺癌铂类化疗敏感性预测的研究[J]. 中华肿瘤防治杂志, 2008,15(17):1285-1288 | |
| [3] | Meng FY, Zheng WY, Liu XL, Song LL, Xu B, Zhang Y . Clinical observation of curative effects of imatinib in treatment of 26 cases of chronic myeloid leukemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2004,25(5):314-315 |
| 孟凡义, 郑维扬, 刘晓力, 宋兰林, 徐兵, 张钰 . 伊马替尼治疗慢性粒细胞白血病26例临床观察[J]. 中华血液学杂志, 2004,25(5):314-315 | |
| [4] | Xu WT, Li R . Efficacy of imatinib mesylate in treatment of advanced gastrointestinal stromal tumors[J]. Di Er Jun Yi Da Xue Xue Bao, 2005,26(5):583-584 |
| 徐文通, 李荣 . 甲磺酸伊马替尼治疗晚期胃肠道恶性间质瘤疗效的初步观察[J]. 第二军医大学学报, 2005,26(5):583-584 | |
| [5] |
Ma D . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. Xun Zheng Yi Xue, 2006,6(5):277-280
doi: 10.3969/j.issn.1671-5144.2006.05.007 |
|
马冬 . 贝伐单抗联合依立替康、氟尿嘧啶/甲酰四氢叶酸对转移性结直肠癌的治疗[J]. 循证医学, 2006,6(5):277-280
doi: 10.3969/j.issn.1671-5144.2006.05.007 |
|
| [6] | Wang T, Luo LL . A systematic review of bevacizumab for non-small cell lung cancer[J]. Zhongguo Shi Yong Yi Yao, 2008,3(5):1-2 |
| 王艇, 罗黎力 . 贝伐单抗治疗晚期非小细胞肺癌的系统评价[J]. 中国实用医药, 2008,3(5):1-2 |